Evaluation of novel fusion proteins derived from extracellular matrix binding domains of LigB as vaccine candidates against leptospirosis in a hamster model

Vaccine

Volumn 29, Issue 43, 2011, Pages 7379-7386

  Cao, Yongguo ^a,b   Faisal, Syed M ^a   Yan, Weiwei ^a   Chang, Yu Chen ^a   McDonough, Sean P ^a   Zhang, Naisheng ^b   Akey, Bruce L ^a   Chang, Yung Fu ^a  

^a Department of Obstetrics Gynecology   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

Extracellular matrix; Fusion protein; Leptospira interrogans; Lig proteins

Indexed keywords

BACTERIUM ANTIBODY; HYBRID PROTEIN; LEPTOSPIROSIS VACCINE; LIGBCON4 7.5 LIGBCEN2 LIPL32 C TERMINUS FUSION PROTEIN; LIGBCON4 LIGBCEN2 FUSION PROTEIN; LIGBCON4 LIGBCEN2 LIPL32 C TERMINUS FUSION PROTEIN; LIGCON PROTEIN; LIGCON4 7.5 LIGBCEN2 FUSION PROTEIN; OUTER MEMBRANE PROTEIN LIPL32; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; EMULSION; EXTRACELLULAR MATRIX; FEMALE; HAMSTER; HISTOPATHOLOGY; IMMUNOGENICITY; LEPTOSPIRA INTERROGANS; LEPTOSPIROSIS; LETHAL DOSE; LUNG HEMORRHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEROTYPE; SURVIVAL; TREATMENT RESPONSE; VACCINE PRODUCTION;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BACTERIAL VACCINES; CRICETINAE; EXTRACELLULAR MATRIX; LEPTOSPIRA; LEPTOSPIROSIS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES, SUBUNIT;

EID: 80053455701     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.070     Document Type: Article

References (47)

1. Bharti A.R., Nally J.E., Ricaldi J.N., Matthias M.A., Diaz M.M., Lovett M.A., et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 2003, 3(12):757-771.
2. Levett P.N. Leptospirosis. Clin Microbiol Rev 2001, 14(2):296-326.
3. McBride A.J., Athanazio D.A., Reis M.G., Ko A.I. Leptospirosis. Curr Opin Infect Dis 2005, 18(5):376-386.
4. Andre-Fontaine G., Branger C., Gray A.W., Klaasen H.L. Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis. Vet Rec 2003, 153(6):165-169.
5. Rodriguez-Gonzalez I., Fillonneau C., Blanchet B., Suard I., Catilina P., Andre-Fontaine G. Efficacy of spirolept vaccine against human leptospirosis as estimated by passive protection of laboratory rodents. Med Mal Infect 2004, 34(5):196-200.
6. Burnette W.N. Recombinant subunit vaccines. Curr Opin Biotechnol 1991, 2(6):882-892.
7. Parma A.E., Sanz M.E., Lucchesi P.M., Mazzonelli J., Petruccelli M.A. Detection of an antigenic protein of Leptospira interrogans which shares epitopes with the equine cornea and lens. Vet J 1997, 153(1):75-79.
8. Chang Y.F., Chen C.S., Palaniappan R.U., He H., McDonough S.P., Barr S.C., et al. Immunogenicity of the recombinant leptospiral putative outer membrane proteins as vaccine candidates. Vaccine 2007, 25(48):8190-8197.
9. Faisal S.M., Yan W., McDonough S.P., Chang Y.F. Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity. Vaccine 2009, 27(3):378-387.
10. Haake D.A., Mazel M.K., McCoy A.M., Milward F., Chao G., Matsunaga J., et al. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. Infect Immun 1999, 67(12):6572-6582.
11. Koizumi N., Watanabe H. Leptospiral immunoglobulin-like proteins elicit protective immunity. Vaccine 2004, 22(11-12):1545-1552.
12. Palaniappan R.U., McDonough S.P., Divers T.J., Chen C.S., Pan M.J., Matsumoto M., et al. Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar Pomona infection. Infect Immun 2006, 74(3):1745-1750.
13. Seixas F.K., da Silva E.F., Hartwig D.D., Cerqueira G.M., Amaral M., Fagundes M.Q., et al. Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge. Vaccine 2007, 26(1):88-95.
14. Silva E.F., Medeiros M.A., McBride A.J., Matsunaga J., Esteves G.S., Ramos J.G., et al. The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 2007, 25(33):6277-6286.
15. Yan W., Faisal S.M., McDonough S.P., Divers T.J., Barr S.C., Chang C.F., et al. Immunogenicity and protective efficacy of recombinant Leptospira immunoglobulin-like protein B (rLigB) in a hamster challenge model. Microbes Infect 2009, 11(2):230-237.
16. Palaniappan R.U., Chang Y.F., Jusuf S.S., Artiushin S., Timoney J.F., McDonough S.P., et al. Cloning and molecular characterization of an immunogenic LigA protein of Leptospira interrogans. Infect Immun 2002, 70(11):5924-5930.
17. Meri T., Murgia R., Stefanel P., Meri S., Cinco M. Regulation of complement activation at the C3-level by serum resistant leptospires. Microb Pathog 2005, 39(4):139-147.
18. Barbosa A.S., Abreu P.A., Vasconcellos S.A., Morais Z.M., Goncales A.P., Silva A.S., et al. Immune evasion of Leptospira species by acquisition of human complement regulator C4BP. Infect Immun 2009, 77(3):1137-1143.
19. Lin Y.P., Chang Y.F. The C-terminal variable domain of LigB from Leptospira mediates binding to fibronectin. J Vet Sci 2008, 9(2):133-144.
20. Lin Y.P., Lee D.W., McDonough S.P., Nicholson L.K., Sharma Y., Chang Y.F. Repeated domains of Leptospira immunoglobulin-like proteins interact with elastin and tropoelastin. J Biol Chem 2009, 284(29):19380-19391.
21. Lin Y.P., McDonough S.P., Sharma Y., Chang Y.F. Leptospira immunoglobulin-like protein B (LigB) binding to the C-terminal fibrinogen αC domain inhibits fibrin clot formation, platelet adhesion and aggregation. Mol Microbiol 2010.
22. Choy H.A., Kelley M.M., Chen T.L., Moller A.K., Matsunaga J., Haake D.A. Physiological osmotic induction of Leptospira interrogans adhesion: LigA and LigB bind extracellular matrix proteins and fibrinogen. Infect Immun 2007, 75(5):2441-2450.
23. Hauk P., Macedo F., Romero E.C., Vasconcellos S.A., de Morais Z.M., Barbosa A.S., et al. In LipL32, the major leptospiral lipoprotein, the C terminus is the primary immunogenic domain and mediates interaction with collagen IV and plasma fibronectin. Infect Immun 2008, 76(6):2642-2650.
24. Lin Y.P., Greenwood A., Yan W., Nicholson L.K., Sharma Y., McDonough S.P., et al. A novel fibronectin type III module binding motif identified on C-terminus of Leptospira immunoglobulin-like protein, LigB. Biochem Biophys Res Commun 2009, 389(1):57-62.
25. Lin Y.P., Raman R., Sharma Y., Chang Y.F. Calcium binds to leptospiral immunoglobulin-like protein, LigB, and modulates fibronectin binding. J Biol Chem 2008, 283(37):25140-25149.
26. Faisal S.M., Yan W., Chen C.S., Palaniappan R.U., McDonough S.P., Chang Y.F. Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters. Vaccine 2008, 26(2):277-287.
27. Faisal S.M., Yan W., McDonough S.P., Chang C.F., Pan M.J., Chang Y.F. Leptosome-entrapped leptospiral antigens conferred significant higher levels of protection than those entrapped with PC-liposomes in a hamster model. Vaccine 2009, 27(47):6537-6545.
28. Faisal S.M., Yan W., McDonough S.P., Mohammed H.O., Divers T.J., Chang Y.F. Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis. Vaccine 2009, 27(44):6129-6136.
29. Ozanne G. Estimation of endpoints in biological systems. Comput Biol Med 1984, 14(4):377-384.
30. Palaniappan R.U., Chang Y.F., Hassan F., McDonough S.P., Pough M., Barr S.C., et al. Expression of leptospiral immunoglobulin-like protein by Leptospira interrogans and evaluation of its diagnostic potential in a kinetic ELISA. J Med Microbiol 2004, 53(Pt 10):975-984.
31. Raman R., Rajanikanth V., Palaniappan R.U., Lin Y.P., He H., McDonough S.P., et al. Big domains are novel ca-binding modules: evidences from big domains of Leptospira immunoglobulin-like (lig) proteins. PLoS One 2010, 5(12):e14377.
32. Vivian J.P., Beddoe T., McAlister A.D., Wilce M.C., Zaker-Tabrizi L., Troy S., et al. Crystal structure of LipL32, the most abundant surface protein of pathogenic Leptospira spp. J Mol Biol 2009, 387(5):1229-1238.
33. Haake D.A. Hamster model of leptospirosis. Curr Protoc Microbiol 2006, Chapter 12 Unit 12E.2.
34. Kline K.A., Falker S., Dahlberg S., Normark S., Henriques-Normark B. Bacterial adhesins in host-microbe interactions. Cell Host Microbe 2009, 5(6):580-592.
35. Langermann S., Mollby R., Burlein J.E., Palaszynski S.R., Auguste C.G., DeFusco A., et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 2000, 181(2):774-778.
36. Langermann S., Palaszynski S., Barnhart M., Auguste G., Pinkner J.S., Burlein J., et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997, 276(5312):607-611.
37. Strindelius L., Folkesson A., Normark S., Sjoholm I. Immunogenic properties of the Salmonella atypical fimbriae in BALB/c mice. Vaccine 2004, 22(11-12):1448-1456.
38. Goluszko P., Goluszko E., Nowicki B., Nowicki S., Popov V., Wang H.Q. Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesin. Infect Immun 2005, 73(1):627-631.
39. Kao D.J., Churchill M.E., Irvin R.T., Hodges R.S. Animal protection and structural studies of a consensus sequence vaccine targeting the receptor binding domain of the type IV pilus of Pseudomonas aeruginosa. J Mol Biol 2007, 374(2):426-442.
40. Pereira Figueira C., Croda J., Choy H.A., Haake D.A., Reis M.G., Ko A.I., et al. Heterologous expression of pathogen-specific genes ligA and ligB in the saprophyte Leptospira biflexa confers enhanced adhesion to cultured cells and fibronectin. BMC Microbiol 2011, 11(1):129.
41. Lucas D.S., Cullen P.A., Lo M., Srikram A., Sermswan R.W., Adler B. Recombinant LipL32 and LigA from Leptospira are unable to stimulate protective immunity against leptospirosis in the hamster model. Vaccine 2011, 29(18):3413-3418.
42. Croda J., Figueira C.P., Wunder E.A., Santos C.S., Reis M.G., Ko A.I., et al. Targeted mutagenesis in pathogenic Leptospira species: disruption of the LigB gene does not affect virulence in animal models of leptospirosis. Infect Immun 2008, 76(12):5826-5833.
43. Murray G.L., Srikram A., Hoke D.E., Wunder E.A., Henry R., Lo M., et al. Major surface protein LipL32 is not required for either acute or chronic infection with Leptospira interrogans. Infect Immun 2009, 77(3):952-958.
44. Lin Y.P., McDonough S.P., Sharma Y., Chang Y.F. Leptospira immunoglobulin-like protein B (LigB) binding to the C-terminal fibrinogen αC domain inhibits fibrin clot formation, platelet adhesion and aggregation. Mol Microbiol 2011, 79(4):1063-1076.
45. Adler B., de la Pena Moctezuma A. Leptospira and leptospirosis. Vet Microbiol 2010, 140(3-4):287-296.
46. Srikram A., Zhang K., Bartpho T., Lo M., Hoke D.E., Sermswan R.W., et al. Cross-protective immunity against leptospirosis elicited by a live, attenuated lipopolysaccharide mutant. J Infect Dis 2011, 203(6):870-879.
47. Challa S., Nally J.E., Jones C., Sheoran A.S. Passive immunization with Leptospira LPS-specific agglutinating but not non-agglutinating monoclonal antibodies protect guinea pigs from fatal pulmonary hemorrhages induced by serovar Copenhageni challenge. Vaccine 2011, 29(27):4431-4434.